Lenalidomide capsules, in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg strengths. Lenalidomide is a medication used to treat types of multiple myeloma, mantle cell lymphoma, follicular lymphoma, marginal
zone lymphoma, and anemia in myelodysplastic syndromes (MDS) in adults.
Dasatinib tablets in 20 mg, 50 mg, 70 mg, 80 mg, 100 mg and 140 mg strengths. Dasatinib is used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML) in adults and children of one year and above.Also Read: Biocon targets mid-teen revenue growth with new product pipeline
It is also used to treat Ph+CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) in adults after other medicines (eg, imatinib) or treatments did not work well. Dasatinib is also used in combination with chemotherapy to treat newly-diagnosed Ph+ALL in children one year and above.
Biocon Pharma also received tentative approval of its ANDA for rivaroxaban tablets USP, in 2.5 mg, 10 mg, 15 mg and 20 mg strengths. Rivaroxaban is used in the treatment of deep vein thrombosis and pulmonary embolism to reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, etc.
Shares of Biocon Ltd ended at ₹314.80, up by ₹9.90, or 3.25%, on the BSE.
Also Read: Biocon launches generic Liraglutide in the UK for diabetes, obesity treatment
(Edited by : Shoma Bhattacharjee)
